Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation

Cromm, Philipp M., Samarasinghe, Kusal T. G., Hines, John, Crews, Craig M.·2018·Journal of the American Chemical Society
DOI 10.1021/jacs.8b08008

Cited by (311)

Items 201–300 of 311

  1. PROTAC technology for prostate cancer treatment
    Zhen Wang, Dingpeng Zhang, Hiroyuki Inuzuka, Wenyi Wei · 2025 · Acta Materia Medica
  2. PROTAC Degraders
    Alessio Ciulli, Oliver Hsia · 2022
  3. Targeted Strategies for Degradation of Key Transmembrane Proteins in Cancer
    Vehary A. Sakanyan, Nina Iradyan, Rodolphe Alves de Sousa · 2023 · BioTech
  4. PROTACs in Ovarian Cancer: Current Advancements and Future Perspectives
    Makenzie Vorderbruggen, Carlos A. Velázquez‐Martínez, Amarnath Natarajan, Adam R. Karpf · 2024 · International Journal of Molecular Sciences
  5. Targeting Moonlighting Enzymes in Cancer
    Chunxu Lin, Mingyang Yu, Ximei Wu, Hui Wang, Min Wei, Luyong Zhang · 2024 · Molecules
  6. Beute für das Proteasom: Gezielter Proteinabbau aus medizinalchemischer Perspektive
    Laura Martina Luh, Ulrike Scheib, Katrin Juenemann, Lars Wortmann, Michael Brands, Philipp M. Cromm · 2020 · Angewandte Chemie
  7. Developing PROteolysis TArgeting Chimeras (PROTACs) for hematologic malignancies
    Yangping Wu, Jingliao Zhang, Xiaofan Zhu, Yingchi Zhang · 2022 · Cancer Letters
  8. From Degraders to Molecular Glues: New Ways of Breaking Down Disease‐Associated Proteins
    Yvonne A. Nagel, Adrian Britschgi, Antonio Ricci · 2021 · Wiley eBooks
  9. Computational Modeling of PROTAC Ternary Complexes as Ensembles Using SILCS-xTAC
    Erik B. Nordquist, Mingtian Zhao, Wenbo Yu, Alexander D. MacKerell · 2025 · Journal of Chemical Information and Modeling
  10. Targeting β-catenin: PROTACs and precision degraders for Wnt-driven cancers
    Jonathan B. Trapani, Kailey P. Caroland, Yashi F. Ahmed, David J. Robbins, Vivian Lee Weiss, Ethan Lee · 2026 · Frontiers in Oncology
  11. Targeting focal adhesion kinase: from molecular mechanisms to next-generation cancer therapeutics
    Jie Chen, Zixuan Bu, Qimin Zhan · 2026 · 中国科学通报：英文版
  12. Linkerology in PROTACs: learnings for proximity-inducing therapeutics
    Rubén Prieto‐Díaz, Aina Urbina, Maria Rodriguez-Rios, Alessio Ciulli · 2026 · Trends in Biochemical Sciences
  13. PROTAC-mediated Target Degradation: A Paradigm Changer in Drug Discovery?
    Philipp M. Cromm, Craig M. Crews, Hilmar Weinmann · 2020 · Royal Society of Chemistry eBooks
  14. Recent Developments in Medicinal Chemistry and Therapeutic Potential of Anti-Cancer PROTACs-Based Molecules
    Muhammad Zafar Irshad Khan, Adila Nazli, Youlu Pan, Jian‐Zhong Chen · 2022 · Current Medicinal Chemistry
  15. Ubiquitination in Cancer Metastasis: Emerging Functions, Underlying Mechanisms, and Clinical Implications
    Ganesh Kumar Barik, Osheen Sahay, Sehbanul Islam, Nikhil Baban Ghate, Bhargab Kalita, Aftab Alam · 2023 · Technology in Cancer Research & Treatment
  16. FAK inhibitors in cancer, a patent review – an update on progress
    Ya‐Xi Ye, Yuyao Cao, Lisheng Xu, Hai-Chao Wang, Xinhua Liu, Hai‐Liang Zhu · 2024 · Expert Opinion on Therapeutic Patents
  17. Amide-to-ester substitution as a strategy for optimizing PROTAC permeability and cellular activity
    Victoria G. Klein, Adam G. Bond, Conner Craigon, R. Scott Lokey, Alessio Ciulli · 2021
  18. Proteolysis-Targeting Chimeras (PROTACs) Based on Macrocyclic Tetrapeptides Selectively Degrade Class I Histone Deacetylases 1–3
    Martin Roatsch, Anja Vogelmann, Daniel Herp, Manfred Jung, Christian Adam Olsen · 2020 · ChemRxiv
  19. Research Progress of PROTACs in Breast Cancer: Subtype-Oriented Target Landscape, Clinical Stratification Evidence, and Engineering Strategies for Translation
    Senyang Guo, Jianhua Liu, Hongmei Zheng, Xinhong Wu · 2026 · Biomedicines
  20. Reimagining GSK-3β Therapeutics in Alzheimer’s Disease: From Inhibition to Activity Normalization and Targeted Degradation
    Emad Manni, Hayder M. Al‐kuraishy, Rabab Eisawy, Ahmed M Abdelaziz, Gaber El‐Saber Batiha · 2026 · Journal of Molecular Neuroscience
  21. PROTACs in platelets: emerging antithrombotic strategies and future perspectives
    Justin S. Trory, Jordan Vautrinot, Carl May, Ingeborg Hers · 2024 · Current Opinion in Hematology
  22. Mechanistic insights into PROTAC-mediated degradation through an integrated framework of molecular dynamics, free energy landscapes, and quantum mechanics: A case study on kinase degraders
    Ashis Kumar Nandy, Kiran Boppana, Samiron Phukan · 2025 · Journal of Computer-Aided Molecular Design
  23. Boosting bioavailability of PROTACs for ovarian cancer: From chemistry to clinical translation
    Mokhtar Saeed Rejili, Md Sadique Hussain, Faouzi Haouala, Yumna Khan, Mudasir Maqbool, Gaurav Gupta · 2025 · Bioorganic Chemistry
  24. Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy?
    Margherita Ambrosini, Giovanni Fucà, Matteo Duca, Silvia Damian, Francesca De Santis, Francesca Corti, Sara Cresta, Filippo de Braud, Massimo Di Nicola · 2021 · Critical Reviews in Oncology/Hematology
  25. Discovery and Characterisation of Highly Cooperative FAK‐Degrading PROTACs
    Robert P. Law, João Nunes, Chun‐wa Chung, Marcus Bantscheff, Karol Buda, Han Dai, John P. Evans, Adam Flinders, Diana Klimaszewska, Antonia J. Lewis et al. · 2021 · Angewandte Chemie
  26. Breaking the Fourth Wall: Modulating Quaternary Associations for Protein Regulation and Drug Discovery
    Marcus J. C. Long, Dziyana Hnedzko, Bo Kyoung Kim, Yimon Aye · 2018 · ChemBioChem
  27. Mechanisms and Design Principles of Proteolysis-Targeting Chimeras and Their Emerging Applications
    Nikola Knoll, Nouri Neamati, Aykut Üren · 2026 · ACS Pharmacology & Translational Science
  28. Identification of a Potent and Selective Focal Adhesion Kinase Proteolysis Targeting Chimera: Targeting Noncatalytic Functions of Focal Adhesion Kinase to Facilitate Antitumor Immunity
    Wei Wei, Guangmei Li, Zhimin Hu, Xiang Hu, Rong Hu, Qi Zhang, Xinyue Li, Tianqiong Yang, Jiuyu Gao, Yu Cao et al. · 2025 · Journal of Medicinal Chemistry
  29. Design and synthesis of JNK1-targeted PROTACs and research on the activity
    Yue Guo, Fengling Liu, Man Chi, Hewen Qian, Ye Zhang, Yaxia Yuan, Shurong Hou, Xiabin Chen, Lei Ma · 2024 · Bioorganic Chemistry
  30. Direct antitumoral effects of sulfated fucans isolated from echinoderms: a possible role of neuropilin-1/β1 integrin endocytosis and focal adhesion kinase degradation
    Antonio Gilclêr Ferreira Lima, Viviane W. Mignone, Francisco Vardiero, Eliene Oliveira Kozlowski, Laila Ribeiro Fernandes, Juliana María Motta, Mauro S.G. Pavão, Camila Castro Figueiredo, Paulo A.S. Mourão, Verônica Morandi · 2023 · Glycobiology
  31. Degradation of FAK-targeting by proteolytic targeting chimera technology to inhibit the metastasis of hepatocellular carcinoma
    Xinfeng Zhang, Shuang Li, MEIRU SONG, Yue Chen, Liangzheng Chang, Zherui Liu, Hongyuan Dai, Yutao Wang, Gangqi Yang, YUN JIANG et al. · 2024 · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
  32. PROTACs in gynecological cancers: Current knowledge and future potential as a treatment strategy
    Fatemeh Movahed, Zahra Ourang, Razieh Neshat, Wael Sheet Hussein, Anwar Salih Saihood, Maythum Shallan Alarajy, Donya Zareii · 2024 · Pathology - Research and Practice
  33. Computational Modeling of PROTAC Ternary Complexes and Linker Design
    Sven A. Miller, Grigorii V. Andrianov, Victoria Mischley, Khadija A. Wharton, Jesse J. Chen, John Karanicolas · 2022
  34. FAK: A Potential Target for Cancer Therapy
    Chao Zhang, Yu Rao · 2025 · ACS Medicinal Chemistry Letters
  35. Hypoxia-activated PROTAC for dual inhibition of FAK and EGFR enables synergistic mechano-chemical cancer therapy
    Keli An, Y F Li, Chunyu Cao, M Wang, Xiaohui Jia, Guorui Jin, Bo Cheng, Yuanbo Jia, Lei Wang, Guo H et al. · 2026 · Neoplasia
  36. Recent Advances of RNA m6A Modifications in Cancer Immunoediting and Immunotherapy
    Shoubao Ma, Tasha Barr, Jianhua Yu · 2023 · Cancer treatment and research
  37. PROteolysis TArgetting Chimeras (PROTACs) Strategy Applied to Kinases: Recent Advances
    Anthony Feral, Guillaume Laconde, Muriel Amblard, Nicolas Masurier · 2020 · Advanced Therapeutics
  38. Targeting STK33: From Inhibition to Degradation
    Siying Zhong, Joanne Wayne · 2021 · Future Medicinal Chemistry
  39. Target Protein Localisation and Its Impact on PROTAC-Mediated Degradation
    Luke M. Simpson, Lorraine Glennie, Jennifer Crooks, Natalia Shpiro, Gopal P. Sapkota · 2022 · SSRN Electronic Journal
  40. Imaging of MAP kinase dynamics reveals endocytic regulation of pulsatile signalling and network re-wiring in response to targeted therapy in EGFR-mutant non-small cell lung cancer
    Alix Le Marois, Sasha Bailey, Steven Hooper, Sunil Kumar, Hugh Sparks, Yuriy Alexandrov, Deborah R. Caswell, Fabian Fröhlich, Karin Schlegelmilch, Karishma Valand et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  41. Predicting PROTAC-targeted Degradation and Designing Androgen Receptor Degraders with AiPROTAC
    Li Zhang, Renhong Sun, Xia Li, Chaowei Ren, Yahui Long, Wenjuan Tan, Xiaolong Wang, Ke Zou, Xiaobao Yang, Min Wu et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  42. Destruction of DNA-binding proteins by programmable O’PROTAC: Oligonucleotide-based PROTAC
    Shao, Jingwei, Yan, Yuqian, Ding, Donglin, Wang, Dejie, He, Yundong, Pan, Yunqian, Yan, Wei, Kharbanda, Anupreet, Li, Hong-yu, Huang, Haojie · 2021
  43. Discovery of a macrocyclic FAK inhibitor GZD-257 for treatment of glioblastoma
    Ting Wu, Yaqing Zuo, Kehui Chen, Ying Xu, Daili Wu, Yi Le, Li Liu, Longjia Yan · 2025 · Bioorganic & Medicinal Chemistry Letters
  44. Design and Synthesis of Novel Candidate CK1δ Proteolysis Targeting Chimeras (PROTACs)
    Malte Arnold, Temi Thompson, Lorraine Glennie, Mattes Hollnagel, Gopal P. Sapkota, Christian Peifer · 2025 · Molecules
  45. Targeting focal adhesion kinase (FAK) in non-small cell lung cancer (NSCLC): Molecular mechanisms and combination therapeutic strategies
    Yihua Zhang, Di Lu, Liying Zhang, Yuna Shao, Zhaowei Yan, Zeyi Liu · 2026 · Biochemical Pharmacology
  46. Targeting Activin Receptor-like Kinase 2 Using Heterobifunctional Protein Degraders
    Daniel T. Webb, Katherine L. Jones, Natsuko Macabuag, Ružica Bago, Joshua Betts, Sumit Bhattacharyya, Steve Clifton, Ryan Tinson, Chigozie Achara, Simon Gilbert et al. · 2026 · Journal of Medicinal Chemistry
  47. Targeted protein degradation: bridging chemical biology and clinical translation
    Yubo Zhang, Jun-wei Fu, Yue Liu, R Y Wu, Yanting Liang, Wei Zhang, Tao Yuan, Hao Zhu, Qiao-Jun He, Bo Yang · 2026 · Acta Pharmacologica Sinica
  48. Development of CDK12 as a Cancer Therapeutic Target and Related Inhibitors
    Biqing Chen, Jiaqi Liu · 2024 · Current Cancer Drug Targets
  49. Future of Trends in the Design and Development of PROTAC
    Popat Kumbhar, Kaustubh Ajit Kolekar, Vikas Kamble, Chukwuebuka Emmanuel Umeyor, John Disouza, Vandana Bharat Patravale · 2024 · Springer eBooks
  50. Targeted Protein Degradation by Proteolysis Targeting Chimeras
    Wu Du · 2022
  51. Exploring the Role of PROTACs for the Treatment of Breast Cancer
    Arzoo Singh Pannu, Ramesh K. Goyal, Shikha Goswami · 2024 · Springer eBooks
  52. Proteolysis Targeting Chimera (PROTACs) in Cancer: From Molecular Mechanisms to Therapeutic Opportunities
    Jing Yang, Qing Qiao, Na Lin, Miaomiao Niu, Lin Su, Boshu Yin · 2025 · Journal of Biochemical and Molecular Toxicology
  53. Structure-guided design of a potent focal adhesion kinase (FAK) degrader via ternary complex modeling and molecular dynamics simulation
    Chenxu Liu, Xiaokang Xu, Yaning Biao, Ya‐Fen Wang, Yajing Zhang · 2025 · Bioorganic Chemistry
  54. Indirect ubiquitination independent of endogenous ubiquitination machinery for targeted protein degradation
    Takafumi Furuhata, Kazuki Yoshida, 藤田 凌嘉, Jotaro Miyamoto, Chiharu Moriyama, Tokiha Masuda-Ozawa, Hikaru Tsuchiya, Yasushi Saeki, Akimitsu Okamoto · 2026 · Communications Chemistry
  55. Inhibition of focal adhesion kinase impairs tumor formation and preserves hearing in a murine model of NF2-related schwannomatosis
    Dana K. Mitchell, Kylee Brewster, Li Jiang, Henry Elmer Mang, Waylan Bessler, Xiaohong Li, Qingbo Lu, Shaomin Qian, Eric York, Sarah K. Morrow et al. · 2026 · Science Advances
  56. Bifunctional proximity-inducing strategies for targeted and programmable post-translational modifications
    Sadiya Tanga, Pallabi Das, Tuhin Baran Samoi, Arpita Hota, Arkadeep Karmakar, Basudeb Maji · 2026 · Advanced Drug Delivery Reviews
  57. Targeting the WNT/β-Catenin Pathway in Hematological Malignancies: From Molecular Pathogenesis to Emerging Therapeutic Strategies
    Ali Keyhani, Hamed Haddad Kashani, Khadijeh Dizaji Asl, Zeinab Mazloumi, Faride kaikavoosnejad, Sahar Sadat Moosavi, Milad Verdi, Ali Rafat, Reza Nejati · 2026 · Biomolecules
  58. Targeted Protein Degradation Chemical Probes
    Carles Galdeano, Xavier Barril · 2020 · Royal Society of Chemistry eBooks
  59. Target Validation—Prosecuting the Target
    Lyn H. Jones · 2021 · Elsevier eBooks
  60. PROTACs in Treatment of Glioma
    Sachin Kumar, Vikas Maharshi · 2024 · Springer eBooks
  61. Modeling of FAK-PROTAC candidates from GSK2256098 analogs for targeted protein degradation
    Vikas Kumar, Shraddha Parate, Hyeon‐Su Ro, Tae Sung Jung, Keun Woo Lee · 2024 · Biochemical and Biophysical Research Communications
  62. Chemoproteomics-Enabled De Novo Discovery of a Metallothionein Degrader Enables Probing Their Role in Cancer Cells
    Brittney Racioppo, Dany Pechalrieu, Daniel Abegg, Brendan G. Dwyer, Neal Thomas Ramseier, Ying Hu, Alexander Adibekian · 2024 · ChemRxiv
  63. Chemoproteomics-Enabled De Novo Discovery of Metallothionein Degraders Facilitates Probing Its Role in Cancer
    Brittney Racioppo, Dany Pechalrieu, Daniel Abegg, Brendan G. Dwyer, Neal Thomas Ramseier, Ying Hu, Alexander Adibekian · 2024 · ChemRxiv
  64. Defeating kinases that promote tumorigenesis through non-catalytic functions with PROTACs - PIM kinase as an example
    Pedro Torres‐Ayuso, John Brognard · 2025 · Expert Opinion on Therapeutic Targets
  65. Faculty Opinions recommendation of Major Advances in Targeted Protein Degradation: PROTACs, LYTACs, and MADTACs.
    John A. Lowe III · 2021 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  66. Cryptotanshinone Inhibits Ovarian Tumor Growth and Metastasis by Degrading c-Myc and Attenuating the FAK Pathway
    Huijun Guo, Guannan Zhao, Yaohong Wang, Wenjing Zhang, Bing‐Mei Zhu, Peixin Dong, Hidemichi Watari, Gábor Tigyi, Junming Yue · 2022 · Research Square
  67. Kinases/Phosphatases | FAK Family
    Steven K. Hanks, Sarah C. Stainbrook · 2021 · Elsevier eBooks
  68. A Structural and Biophysical Perspective of Degrader Activity Through Ternary Complex Formation
    Morgan S. Gadd, Marine C. Aublette · 2022 · Wiley eBooks
  69. Targeted Protein Degradation of Metalloenzymes
    Conor O’Herin, Seth M. Cohen · 2025 · Wiley eBooks
  70. Degraders of signal transduction receptors
    Xin Luan, Ye Wu · 2025 · Elsevier eBooks
  71. PROTACS- targeted protein degradation as a path to precision cancer therapeutics
    Hannah R Gatley, Paul B. Fisher, Swadesh Kumar Das · 2025 · Advances in cancer research
  72. Establishing selectivity of FAK-paxillin PPI inhibitor using pulldown proteomics and a focal adhesion protein selectivity panel
    Hunter O'Brien, Brock Hay, Huzaifah Sheikh, Liam McCreary, Krishna Parsawar, Timothy A. Marlowe · 2025 · Biochemistry and Biophysics Reports
  73. Chemical synthesis of novel aminopyrimidin-4-yl-1H-pyrazole derivatives as spleen tyrosine kinase (SYK) inhibitors
    K. V. Rajasheker, M. S. Pallavi, Pallavi Singh, Victor Stupin, Ekaterina Vladimirovna Silina, Kavitharaj Varadaraju, Mohammad Yahya Alfaifi, Ali Abdullah Shati, Serag Eldin I. Elbehairi, Chandan Shivamallu et al. · 2026 · Scientific Reports
  74. PROTAC-mediated regulation of programmed cell death: From molecular mechanisms to therapeutic breakthroughs
    Hangqi Huang, Aoli Deng, Feifan Pan, Yajuan Lu, Lulu Chen, Jinghao Cao, Qin Tang, Yingchao Liu, Yunyi Wu, Jing Du et al. · 2026 · The Innovation
  75. Conception et synthèse d’inhibiteurs duaux de DYRK1A et CLK1, kinases impliquées dans la maladie d’Alzheimer
    Clémentine Pescheteau · 2021
  76. Curated set of tool compounds to probe PYK2 and FAK signaling in Alzheimer's disease
    Pathum Manjula Weerawarna, Cynthia D. Jesudason, Karen L. Lobb, Emily R. Mason, Xiaoping Gu, Shaoyou Chu, Timothy I. Richardson · 2026 · Alzheimer s & Dementia
  77. Integrative structural and computational analysis reveals potential design principles for efficient PROTAC degraders
    Yi Zhou, Yu Cao, Xinyue Ma, Hao Yang, Siyuan Tian, Chenjia Zhu, Yilin Tang, Ran Zhang, José N. Onuchic, Fang Bai · 2026 · Cell Reports Physical Science
  78. Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer
    Kendelle Joan Murphy, Cecilia R. Chambers, Daniel A. Reed, Lily M. Channon, Niamh EP Mills, Sophie E McKay, Victoria Lee, Anna E. Howell, Alice M. H. Tran, Max Nobis et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  79. Targeted protein degradation technologies for modulating cell-cell communication
    Yingchuan Lu, Ming Wang · 2026 · Scientia Sinica Chimica
  80. Design, synthesis, and biological evaluation of the first fibroblast growth factor receptor 4 PROTAC degrader
    Yuehui Li, Yu Du, Ping Deng, Yi Yang, Yue Wu, Xiaomeng Sun, Qiuzhu Chen, Juntong Yang, Qihua Zhu, Zongjie Gan et al. · 2026 · Bioorganic Chemistry
  81. Proteolysis Targeting Chimeras (PROTACs): Design and Mechanism
    Xiajing Lin, Yan Zhang, Chenhui Wang · 2026 · Handbook of experimental pharmacology
  82. PROTAC as a Potential Toolbox for the Discovery of New Targets and Drugs
    Mengjun Ma, Xiaolei Meng, Chong Qin · 2026 · Handbook of experimental pharmacology
  83. Targeted degradation of VEGFR2 via PROTAC encapsulated by cRGD-liposome reverses pathological corneal neovascularization
    Ke Feng, Mingyan Wei, Wenying Guan, Bo Yan, Shinan Wu, Xiaodong Chen, Jiaoyue Hu, Panqin Ma, Caihong Huang, Yi Han et al. · 2026 · Biomaterials
  84. Targeting extracellular matrix mechanobiology to suppress solid tumor progression
    Keefer Boone, Raghu Vamsi Kondapaneni, Sarah Libring, Cynthia A. Reinhart‐King · 2026 · Cancer Letters
  85. Disease-guided targeted protein degradation and clearance: matching strategies to pathological protein states
    Tianyu Wang, Chenbo Ji, Tianyu Zhao · 2026 · Frontiers in Medicine
  86. BindingDB Entry 50017954: PROTACs to address the challenges facing small molecule inhibitors.
    BindingDB · 2023 · UC San Diego
  87. BindingDB Entry 50022745: Targeting focal adhesion kinase (FAK) in cancer therapy: A recent update on inhibitors and PROTAC degraders.
    BindingDB · 2026 · UC San Diego
  88. BindingDB Entry 50014967: Amide-to-Ester Substitution as a Strategy for Optimizing PROTAC Permeability and Cellular Activity.
    BindingDB · 2023 · UC San Diego
  89. BindingDB Entry 50018749: PROTAC: A promising technology for cancer treatment.
    BindingDB · 2024 · UC San Diego
  90. BindingDB Entry 50019525: PROTACS: A technology with a gold rush-like atmosphere.
    BindingDB · 2024 · UC San Diego
  91. BindingDB Entry 50018545: Blocking Non-enzymatic Functions by PROTAC-Mediated Targeted Protein Degradation.
    BindingDB · 2024 · UC San Diego
  92. BindingDB Entry 50007767: Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
    BindingDB · 2021 · UC San Diego
  93. BindingDB Entry 50015218: Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor.
    BindingDB · 2023 · UC San Diego
  94. BindingDB Entry 50021665: The application of PROTAC in HDAC.
    BindingDB · 2025 · UC San Diego
  95. BindingDB Entry 50010796: Discovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer.
    BindingDB · 2021 · UC San Diego
  96. BindingDB Entry 50018566: Development and Utility of a PAK1-Selective Degrader.
    BindingDB · 2024 · UC San Diego
  97. BindingDB Entry 50022994: Discovery of Novel PROTAC-Based HPK1 Degraders with High Potency and Selectivity for Cancer Immunotherapy.
    BindingDB · 2026 · UC San Diego
  98. BindingDB Entry 50016839: VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives.
    BindingDB · 2023 · UC San Diego
  99. BindingDB Entry 50014922: Discovery of a Brigatinib Degrader SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile.
    BindingDB · 2023 · UC San Diego
  100. BindingDB Entry 50022651: Development of novel focal adhesion kinase (FAK) inhibitors for targeting cancer: Structural insights and therapeutic potential.
    BindingDB · 2026 · UC San Diego